Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma

J. J. Costanzi, M. R. Cooper, J. H. Scarffe, H. Ozer, S. S. Grubbs, R. W. Ferraresi, Richard B Pollard, R. J. Spiegel

Research output: Contribution to journalArticlepeer-review

93 Scopus citations


A multicenter phase II study of INTRON, recombinant alpha-2 interferon (Schering Corp, Kenilworth, NJ), in patients with relapsing or refractory myeloma was initiated. Patients received either intravenous therapy for two weeks followed by subcutaneous therapy or subcutaneous dosing from initiation of treatment. Of 38 evaluable patients, 19 were refractory and 19 had relapses at entry. Twenty-five of 38 had received prior treatment with multiple drugs. Responses were seen among 2/19 refractory patients and 5/19 relapsing patients. Three of seven responders continue to respond for more than one year while receiving maintenance therapy. Most patients experienced improvement in bone pain, and one patient, with a complete response, had healing of bone lesions. Survival curves show a statistically significant improvement in survival for responders v nonresponders. INTRON was well-tolerated with only four patients discontinuing treatment due to adverse effects. Thirty-two percent of patients had hematologic toxicity requiring dose adjustment; however, there was no evidence of cumulative hematologic toxicity. No patients developed serum neutralizing factors to interferon. Additional trials are warranted to study the activity of INTRON in previously untreated patients.

Original languageEnglish (US)
Pages (from-to)654-659
Number of pages6
JournalJournal of Clinical Oncology
Issue number5
StatePublished - 1985
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma'. Together they form a unique fingerprint.

Cite this